Bioxodes’ BIOX-101 Shows Breakthrough ICH Trial Results
Final results from BIRCH, a 23-patient multicenter, randomized, open-label Phase 2a trial in spontaneous intracerebral hemorrhage, met the primary...
Structure to Present New Diabetes Combination Data at ADA
Structure Therapeutics will take an oral small-molecule GLP-1 receptor agonist into the ADA spotlight with Phase 2b ACCESS data...
FDA Fast Tracks Scancell’s Melanoma Drug After Phase 2 Data
Progression-free survival reached 77% at 20 months in the target HLA-selected population of Scancell’s Phase 2 SCOPE trial when...
ERAS-0015 Shows Surging Promise in KRAS Mutant Tumors
Unconfirmed overall response rates from early Phase 1 readouts of ERAS-0015, a once-daily oral pan-RAS molecular glue, were 62%...
Altimmune’s Remarkable $225M Offering Sees Surging Demand
Altimmune priced a $225 million underwritten offering built around 64.25 million common shares paired one-for-one with immediately exercisable $3.00...
Oral Semaglutide: A Breakthrough for Kids with Diabetes?
In the Phase 3a PIONEER TEENS study (n=132), oral semaglutide delivered a statistically significant 0.83% greater reduction in HbA1c...
Clinuvel Gets EMA Advice for Pivotal Phase III Vitiligo Study
EMA has issued final scientific advice clearing Clinuvel’s pivotal vitiligo trial to use a “totality of evidence” assessment anchored...
Nectero Reports 2-Year Safety and Efficacy Data for AAA
In a 46-patient first-in-human study of small- to medium-sized abdominal aortic aneurysms (AAA), Nectero’s investigational Nectero EAST System delivered...
KOL Event Spotlights Lasofoxifene for Resistant Cancer
Phase 2 signals continue to support lasofoxifene’s pursuit of ESR1‑mutated, ER+/HER2‑ metastatic breast cancer. In ELAINE‑1, lasofoxifene outperformed fulvestrant...
Psyence Biomed Doses First Patient in Adjustment Disorder Trial
Psyence Biomedical has dosed the first patient in its Phase IIb study of NPX-5, a GMP-compliant, nature-derived psilocybin candidate,...